Holly Vance's most recent trade in Neoleukin Therapeutics Inc was a trade of 100,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Aug. 3, 2021.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Neoleukin Therapeutics Inc | Holly Vance | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2021 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
Neoleukin Therapeutics Inc | Holly Vance | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Oct 2020 | 220,000 | 220,000 | - | - | Stock Option (Right to Buy) |